Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.

ClinicalTrials.gov 1 recruiting now later-stage tilt small index

Patients With Non-Small Cell Lung Cancer: later-stage trial registry

1 of 1 indexed Patients With Non-Small Cell Lung Cancer trials are currently recruiting, with more weight in Phase 3-4.

Corpus placement: #11,370 of 28,707 conditions by registered trial count.

1 US clinical trials · 1 currently recruiting · #11,370 of 28,707 conditions by registered trial count

Patients With Non-Small Cell Lung Cancer: 1 US clinical trial tracked, 1 recruiting.

Patients With Non-Small Cell Lung Cancer is the subject of 1 registered US clinical trials on ClinicalTrials.gov, 1 of them currently open to new participants. 1 are in Phase 3-4 (later-stage) and 0 in Phase 1-2 (earlier-stage). The most active sponsor is OSE Immunotherapeutics, running 1 of these trials.

Enrollment posture brief

Registry condition patients-with-non-small-cell-lung-cancer

OPEN 1 | RECR 100% | LATE 1 | EARLY 0 | RANK #11370 | SPON 1

Nearest open-share peer: Aortic Arch Aneurysm (100% recruiting · 5 trials)

Patients With Non-Small (th…100%Ablation80%ACL Reconstruction80%Abuse, Drug60%Acceptability60%
Open-enrollment share among volume-matched conditions near Patients With Non-Small Cell Lung Cancer

Patients With Non-Small Cell Lung Cancer lists 1 open slots (100% of 1 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →

Key findings

What ClinicalTrials.gov does not surface for Patients With Non-Small Cell Lung Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.

  1. Patients With Non-Small Cell Lung Cancer is recruiting above its size-band peers.

    1 of 1 indexed trials (100%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.

Phase 31

Phase Distribution

PhaseTrial count
Phase 3 1

Top Sponsors

Named interventions

Most-linked intervention names on Patients With Non-Small Cell Lung Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.

NGS HLAA2 assay Device
1 trials
OSE2101 Drug
1 trials
Docetaxel Drug
1 trials

US sites by state

Facility locations filed on Patients With Non-Small Cell Lung Cancer trials. A trial with sites in several states counts in each.

Florida 1 trials
Connecticut 1 trials
Colorado 1 trials
California 1 trials

Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.

What to do with this Patients With Non-Small Cell Lung Cancer page

1 registered trials, 1 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.

  • 1 Patients With Non-Small Cell Lung Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
  • OSE Immunotherapeutics sponsors the most Patients With Non-Small Cell Lung Cancer trials on record, review their full trial history before evaluating a specific study. See OSE Immunotherapeutics's trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Patients With Non-Small Cell Lung Cancer condition card totals 1 registered trials; most-linked intervention NGS HLAA2 assay; top US site state Florida. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.